Preethi Sundaram's Insider Trades & SAST Disclosures
Preethi Sundaram's most recent trade in Catalyst Pharmaceuticals Inc was a trade of 16,667 Restricted Stock Units done . Disclosure was reported to the exchange on Feb. 14, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Preethi Sundaram.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Catalyst Pharmaceuticals Inc | Preethi Sundaram | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 16,667 | 678,432 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | Preethi Sundaram | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 16,667 | 50,970 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | Preethi Sundaram | Chief Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 14 Feb 2025 | 5,965 | 45,005 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | Preethi Sundaram | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2024 | 6,667 | 695,099 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | Preethi Sundaram | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2024 | 6,667 | 36,648 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | Preethi Sundaram | Chief Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 27 Dec 2024 | 2,345 | 34,303 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | Preethi Sundaram | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 6,855 | 701,766 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | Preethi Sundaram | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 6,855 | 32,396 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | Preethi Sundaram | Chief Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 09 Dec 2024 | 2,415 | 29,981 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | Preethi Sundaram | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 137,553 | 691,812 | - | - | Options to purchase common stock | |
| Catalyst Pharmaceuticals Inc | Preethi Sundaram | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 16,809 | 708,621 | - | - | Options to purchase common stock | |
| Catalyst Pharmaceuticals Inc | Preethi Sundaram | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 16,667 | 554,259 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | Preethi Sundaram | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 16,667 | 31,566 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | Preethi Sundaram | Chief Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 15 Feb 2024 | 6,025 | 25,541 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | Preethi Sundaram | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2023 | 6,666 | 17,308 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | Preethi Sundaram | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2023 | 6,666 | 570,926 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | Preethi Sundaram | Chief Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 27 Dec 2023 | 2,409 | 14,899 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | Sundaram Preethi | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2023 | 143,193 | 557,027 | - | - | Options to purchase common stock | |
| Catalyst Pharmaceuticals Inc | Preethi Sundaram | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2023 | 20,565 | 577,592 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | Preethi Sundaram | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2023 | 16,666 | 413,834 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | Preethi Sundaram | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2023 | 16,666 | 16,666 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | Preethi Sundaram | Chief Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 15 Feb 2023 | 6,024 | 10,642 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | Preethi Sundaram | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Dec 2022 | 68,000 | 410,500 | - | - | Options to purchase common stock | |
| Catalyst Pharmaceuticals Inc | Preethi Sundaram | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Dec 2022 | 20,000 | 430,500 | - | - | Restricted stock units | |
| Catalyst Pharmaceuticals Inc | Preethi Sundaram | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.49 per share. | 11 Nov 2022 | 56,786 | 56,786 (0%) | 0% | 5.5 | 311,755 | Common stock, par value $0.001 per share |
| Catalyst Pharmaceuticals Inc | Preethi Sundaram | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2022 | 56,786 | 342,500 | - | - | Options to purchase common stock | |
| Catalyst Pharmaceuticals Inc | Preethi Sundaram | Chief Strategy Officer | Sale of securities on an exchange or to another person at price $ 16.50 per share. | 11 Nov 2022 | 28,393 | 0 (0%) | 0% | 16.5 | 468,485 | Common stock, par value $0.001 per share |
| Catalyst Pharmaceuticals Inc | Preethi Sundaram | Chief Strategy Officer | Sale of securities on an exchange or to another person at price $ 16.25 per share. | 11 Nov 2022 | 28,393 | 28,393 (0%) | 0% | 16.2 | 461,386 | Common stock, par value $0.001 per share |
| Catalyst Pharmaceuticals Inc | Preethi Sundaram | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2022 | 18,214 | 399,286 | - | - | Options to purchase common stock | |
| Catalyst Pharmaceuticals Inc | Preethi Sundaram | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.49 per share. | 15 Sep 2022 | 18,214 | 18,214 (0%) | 0% | 5.5 | 99,995 | Common stock, par value $0.001 per share |
| Catalyst Pharmaceuticals Inc | Preethi Sundaram | Chief Strategy Officer | Sale of securities on an exchange or to another person at price $ 14.49 per share. | 15 Sep 2022 | 18,214 | 0 (0%) | 0% | 14.5 | 263,921 | Common stock, par value $0.001 per share |
| Catalyst Pharmaceuticals Inc | Preethi Sundaram | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 50,000 | 417,500 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | Preethi Sundaram | Chief Product Devel. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Dec 2021 | 67,500 | 367,500 | - | - | Options to purchase common stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges